Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 322

1.

Clinical outcomes after an unstructured treatment interruption in children and adolescents with perinatally acquired HIV infection.

Saitoh A, Foca M, Viani RM, Heffernan-Vacca S, Vaida F, Lujan-Zilbermann J, Emmanuel PJ, Deville JG, Spector SA.

Pediatrics. 2008 Mar;121(3):e513-21. doi: 10.1542/peds.2007-1086.

PMID:
18310171
2.

Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy.

Rutstein RM, Gebo KA, Flynn PM, Fleishman JA, Sharp VL, Siberry GK, Spector SA.

Med Care. 2005 Sep;43(9 Suppl):III15-22.

PMID:
16116305
3.

[Treatment interruption in 30 HIV-infected patients with successful viral suppression under highly active antiretroviral treatment].

Pavie J, Porcher R, Fournier S, André F, Tournoux C, Palmer P, Rabian C, Jean-Michel M.

Presse Med. 2005 Jun 4;34(10 Suppl):1S8-13. French.

PMID:
16025661
4.
5.

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.

Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.

AIDS. 2008 Aug 20;22(13):1583-8. doi: 10.1097/QAD.0b013e328305bd77.

PMID:
18670217
6.

CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.

Mussini C, Bedini A, Borghi V, Guaraldi G, Esposito R, Barchi E, Enilia R, Cozzi-Lepri A, Philips AN, Ortolani P, Bratt G, Eriksson LE, Sighinolfi L, Cossarizza A, d'Arminio Monforte A, De Luca A, Di Giambenedetto S, Antinori A; International Study Group on CD4-monitored Treatment Interruptions.

AIDS. 2005 Feb 18;19(3):287-94.

PMID:
15718839
7.

Treatment interruption for virological failure or as sparing regimen in children with chronic HIV-1 infection.

Monpoux F, Tricoire J, Lalande M, Reliquet V, Bebin B, Thuret I.

AIDS. 2004 Dec 3;18(18):2401-9.

PMID:
15622316
8.

Response to changes in antiretroviral therapy after genotyping in human immunodeficiency virus-infected children.

Cohen NJ, Oram R, Elsen C, Englund JA.

Pediatr Infect Dis J. 2002 Jul;21(7):647-53.

PMID:
12237597
9.
10.

Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.

Nemes E, Lugli E, Nasi M, Ferraresi R, Pinti M, Bugarini R, Borghi V, Prati F, Esposito R, Cossarizza A, Mussini C.

AIDS. 2006 Oct 24;20(16):2021-32.

PMID:
17053348
11.

Hospital-based directly observed therapy for HIV-infected children and adolescents to assess adherence to antiretroviral medications.

Glikman D, Walsh L, Valkenburg J, Mangat PD, Marcinak JF.

Pediatrics. 2007 May;119(5):e1142-8. Epub 2007 Apr 23.

PMID:
17452493
12.

CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy.

Boschi A, Tinelli C, Ortolani P, Moscatelli G, Morigi G, Arlotti M.

AIDS. 2004 Dec 3;18(18):2381-9.

PMID:
15622314
13.

Neurocognitive functioning in pediatric human immunodeficiency virus infection: effects of combined therapy.

Shanbhag MC, Rutstein RM, Zaoutis T, Zhao H, Chao D, Radcliffe J.

Arch Pediatr Adolesc Med. 2005 Jul;159(7):651-6.

PMID:
15996999
14.

Thymic volume predicts CD4 T-cell decline in HIV-infected adults under prolonged treatment interruption.

Molina-Pinelo S, Vivancos J, De Felipe B, Soriano-Sarabia N, Valladares A, De la Rosa R, Vallejo A, Leal M.

J Acquir Immune Defic Syndr. 2006 Jun;42(2):203-6.

PMID:
16760798
15.

Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.

Storm DS, Boland MG, Gortmaker SL, He Y, Skurnick J, Howland L, Oleske JM; Pediatric AIDS Clinical Trials Group Protocol 219 Study Team.

Pediatrics. 2005 Feb;115(2):e173-82. Epub 2005 Jan 3.

PMID:
15629958
16.

Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of Antiretroviral-Naive Patients.

d'arminio Monforte A, Cozzi-Lepri A, Phillips A, De Luca A, Murri R, Mussini C, Grossi P, Galli A, Zauli T, Montroni M, Tundo P, Moroni M; Italian Cohort of Antiretroviral-Naive Patients Study Group.

J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):407-16.

PMID:
15764957
17.

Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.

Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR 3rd; Pediatric AIDS Clinical Trials Group 219/219C Study Team.

Clin Infect Dis. 2008 Feb 15;46(4):507-15. doi: 10.1086/526524.

18.

Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400 x 10(6) cells/l.

Thiébaut R, Pellegrin I, Chêne G, Viallard JF, Fleury H, Moreau JF, Pellegrin JL, Blanco P.

AIDS. 2005 Jan 3;19(1):53-61.

PMID:
15627033
19.

Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN).

Pogány K, van Valkengoed IG, Prins JM, Nieuwkerk PT, van der Ende I, Kauffmann RH, Kroon FP, Verbon A, Nievaard MF, Lange JM, Brinkman K.

J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):395-400. Erratum in: J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):607. Vanvalkengoed, Irene G [corrected to van Valkengoed, Irene G M].

PMID:
17195761
20.

Immunological predictors of CD4+ T cell decline in antiretroviral treatment interruptions.

Seoane E, Resino S, Moreno S, de Quiros JC, Moreno A, Rubio R, Gonzalez-García J, Arribas JR, Pulido F, Muñoz-Fernández MA.

BMC Infect Dis. 2008 Feb 26;8:20. doi: 10.1186/1471-2334-8-20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk